Table 2.
Annual national cost estimates of snakebite in US$, 2018
| Author, year |
Country |
Perspective |
Study approach |
Annual number of snakebite patients |
Source of annual incident cases |
Annual national cost estimates in US$2018 with cost contribution to total costs |
|||
|---|---|---|---|---|---|---|---|---|---|
|
Direct medical costs (%) |
Direct non-medical costs (%) |
Indirect costs (%) |
Total costs |
||||||
| Mashhadi, 2017 [28] |
Iran |
Societal |
Incidence-based |
5,379 |
Annual report |
2 658 464 (68.01%) |
278 665 (7.13%) |
971 612 (24.86%) |
3,908,741 |
| Kasturiratne, 2017 [5] |
Sri Lanka |
Societal |
Prevalence-based |
80,277 |
Extrapolated from community survey and previous studies |
10 647 355 (77.14%) |
1 338 614 (9.70%) |
181,6581 (13.16%) |
13,802,550 |
| Gampini, 2016 [40] | Burkina Faso | Patients | Prevalence-based | 22,337 | Estimated from previous studies | 126 319 (100.00%) | NR | NR | 126,319 |
N/A – not applicable, NR – not reported